

News Release

October 23, 2006

Astellas, Toyo Pharmar, and ASKA Pharmaceutical Compromised for Infringement of Patent on Harnal[®] Capsule

Japan, October 23, 2006 - Astellas Pharma Inc. ("Astellas"; headquarters: Tokyo; President and CEO: Masafumi Nogimori) today announced that Astellas, Toyo Pharmar Co., Ltd. ("Toyo Pharmar"; headquarters: Kanazawa), and ASKA Pharmaceutical Co., Ltd. ("ASKA Pharmaceutical"; headquarters: Tokyo) have reached a settlement in the patent infringement lawsuit, which Astellas filed on November 29, 2005 with the Tokyo District Court demanding that Toyo Pharmar and ASKA Pharmaceutical stop infringing Astellas' patent rights on its modified release formulation of tamsulosin hydrochloride (brand name: Harnal® 0.1 mg/0.2 mg Capsules).

The modified release formulation patent on tamsulosin hydrochloride has terminated on March 6, 2006.

#######

Contacts for inquiries or additional information

Astellas Pharma Inc.

Corporate Communications

Tel: +81-3-3244-3201 Fax: +81-3-5201-7473

http://www.astellas.com